Objective: The purpose of this study was to investigate the expression of MUC1, MUC2, MUC5AC and MUC5B in breast mucinous lesions. Methods: Immunohistochemical staining of MUC1, MUC2, MUC5AC, MUC5B and synaptophysin was performed in 78 cases of mucinous carcinoma (MC), 36 cases of mucocele-like lesions (MLL) and 13 cases of solid papillary carcinoma (SPC). MC was classified as type A or type B and MLL was classified as MLL, MLL with atypical ductal hyperplasia and MLL with ductal carcinoma in situ. Results: MUC1 was expressed in MC type A and MLL with luminal/apical pattern, while MC type B and SPC showed membrano-cytoplasmic expression of MUC1 (p < 0.001). A luminal/apical or luminal/apical + cytoplasmic pattern of MUC2 expression was observed in MC type A, while MC type B and SPC showed membrano-cytoplasmic MUC2 expression (p < 0.001). On MUC5B staining, MC type A and MLL were negative, while MC type B and SPC showed membrano-cytoplasmic expression (p = 0.011). The positive rate for synaptophysin was higher in MC type B and SPC than in MLL and MC type A (p = 0.001). Conclusions: Similar MUC phenotypes were observed between MLL and MC type A and between MC type B and SPC.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.